Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

Código QR

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

Stanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schwartz SS, Katz A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	combination therapy dapagliflozin metformin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/f459a502a70e4328a6a2f9aa92ee6fc3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses R
Publicado: (2010)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta M, et al.
Publicado: (2021)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
por: Hwee-Yeong Ng, et al.
Publicado: (2021)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
por: I Yu Demidova, et al.
Publicado: (2009)

The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats
por: Gong Lei, et al.
Publicado: (2020)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Metformin effects to carbohydrate and lipids metabolism in impaired glucose tolerance patients.
por: Alexander Vasil'evich Dreval', et al.
Publicado: (2010)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
por: A. M. Mkrtumyan, et al.
Publicado: (2021)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer MF, et al.
Publicado: (2016)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020)

Metformin Induces Ultrastructural Alterations in Hepatocytes of Spontaneously Hypertensive Rats
por: Gharbaran,Rajendra
Publicado: (2014)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Soon-Jib Yoo, et al.
Publicado: (2021)

Enhanced intestinal 2-deoxy-2-[18F]fluoro-D-glucose uptake under metformin is not fully suppressed by loperamide
por: Nobashi Tomomi, et al.
Publicado: (2018)

Multidimensional effects of metformin in patients with type 2 diabetes
por: Lyudmila A. Ruyatkina, et al.
Publicado: (2017)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Muhammad Shahzeb Khan, et al.
Publicado: (2019)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim Y, et al.
Publicado: (2012)

Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia
por: Gebrie D, et al.
Publicado: (2021)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021)

Metformin action over gut microbiota is related to weight and glycemic control in gestational diabetes mellitus: A randomized trial
por: María Molina-Vega, et al.
Publicado: (2022)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients
por: Cristina Ma Díaz-Perdigones, et al.
Publicado: (2022)

Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
por: Zhang Q, et al.
Publicado: (2020)

DEVELOPMENT, COMPUTATIONAL STUDIES AND VALIDATION OF SPECTROPHOTOMETRIC METHOD OF METFORMIN HYDROCHLORIDE IN PHARMACEUTICAL FORMULATIONS
por: Judeh,Ahmed Abu, et al.
Publicado: (2020)

Metformin Protects Against Thioacetamide Induced Liver injury in Rats
por: Al-Hashem,Fahaid, et al.
Publicado: (2018)

Metformin Pretreatment Ameliorates Diabetic Nephropathy Induced by a Combination of High Fat Diet and Streptozotocin in Rats
por: Dallak,Mohammad, et al.
Publicado: (2018)

Metformin and cancer mortality
por: Lev Mikhaylovich Bershteyn
Publicado: (2010)

Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
por: Muhammad Afzal, et al.
Publicado: (2021)

Geroprotectors as a therapeutic strategy for COPD – where are we now?
por: Miłkowska-Dymanowska J, et al.
Publicado: (2017)

Glucoherb versus metformin on glycemic markers and glycosylated hemoglobin in prediabetes patients; a clinical trial study
por: Iman Izadi, et al.
Publicado: (2021)

Evaluation of the Effect of an Aqueous Extract of Azadirachta indica (Neem) Leaves and Twigs on Glycemic Control, Endothelial Dysfunction and Systemic Inflammation in Subjects with Type 2 Diabetes Mellitus – A Randomized, Double-Blind, Placebo-Controlled Clinical Study
por: Pingali U, et al.
Publicado: (2020)

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Na Wang, et al.
Publicado: (2019)

High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
por: Hiroyuki Umino, et al.
Publicado: (2018)